
Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease
— Lead clinical asset AZR-MD-001 for Meibomian gland dysfunction to advance through registration study — Meibomian gland dysfunction is the leading cause of Dry Eye […]


